References

Ackroyd-Stolarz, S., Hartnell, N., & Mackinnon, N. J. (2006). Demystifying medication safety: Making sense of the terminology. Research in Social and Administrative Pharmacy, 2, 280–289.

Ahlbeck, K. (2011). Opioids: A two-faced Janus. Current Medical Research and Opinion, 27, 439–448.

Andreaggi, C. A., Novak, E. A., Mirabile, M. E., Sampathkumar, S., Gray, M. P., He, M., & Kane-Gill, S. L. (2020). Safety concerns reported by consumers, manufacturers and healthcare professionals: A detailed evaluation of opioid-related adverse drug reactions in the FDA database over 15 years. Pharmacoepidemiology and Drug Safety, 29, 1627–1635.

Aronson, J. K. (2009). Medication errors: What they are, how they happen, and how to avoid them. QJM, 102, 513–521.

Bailey, J. E., Campagna, E., & Dart, R. C. (2009). The underrecognized toll of prescription opioid abuse on young children. Annals of Emergency Medicine, 53, 419–424.

Baldo, P., Francescon, S., & Fornasier, G. (2018). Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology. International Journal of Clinical Pharmacy, 40, 748–753.

Bialas, P., Maier, C., Klose, P., & Häuser, W. (2020). Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: Systematic review and meta-analysis of open-label extension trials with a study duration ≥ 26 weeks. European Journal of Pain, 24, 265–278.

Bouvy, J. C., De Bruin, M. L., & Koopmanschap, M. A. (2015). Epidemiology of adverse drug reactions in Europe: A review of recent observational studies. Drug Safety, 38, 437–453.

Branford, R., Droney, J., & Ross, J. (2012). Opioid genetics: The key to personalized pain control? Clinical Genetics, 82, 301–310.

Brophy, T. J., Spiller, H. A., Casavant, M. J., Chounthirath, T., Smith, M. D., & Xiang, H. (2014). Medication errors reported to US poison control centers, 2000–2012. Clinical Toxicology, 52, 880–888.

Callahan, D. (1998). Managed care and the goals of medicine. Journal of the American Geriatrics Society, 46, 385–388.

Cassidy, N., Duggan, E., Williams, D. J. P., & Tracey, J. A. (2011). The epidemiology and type of medication errors reported to the National Poisons Information Centre of Ireland. Clinical Toxicology, 49, 485–491.

Chatterton, C. N., & Handy, R. P. (2023). Fentanyl concentrations in ligated femoral blood in the presence and absence of NPS benzodiazepine drugs: A review of over 1250 benzo-dope/fentanyl toxicity cases in Alberta, Canada. Forensic Science International, 350, 111777.

Chiappini, S., Vickers-Smith, R., Guirguis, A., Corkery, J. M., Martinotti, G., Harris, D. R., & Schifano, F. (2022). Pharmacovigilance signals of the opioid epidemic over 10 years: Data mining methods in the analysis of pharmacovigilance datasets collecting adverse drug reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). Pharmaceuticals, 15, 675.

Chou, R., Turner, J. A., Devine, E. B., Hansen, R. N., Sullivan, S. D., Blazina, I., Dana, T., Bougatsos, C., & Deyo, R. A. (2015). The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine, 162, 276–286.

Cobaugh, D. J., & Krenzelok, E. P. (2006). Adverse drug reactions and therapeutic errors in older adults: A hazard factor analysis of poison center data. American Journal of Health-System Pharmacy, 63, 2228–2234.

Coleman, J. J., & Pontefract, S. K. (2016). Adverse drug reactions. Clinical Medicine, 16, 481.

Compton, W. M., & Jones, C. M. (2019). Epidemiology of the U.S. opioid crisis: The importance of the vector. Annals of the New York Academy of Sciences, 1451, 130–143.

Compton, W., Valentino, R., & DuPont, R. (2020). Polysubstance use in the U.S. opioid crisis. Molecular Psychiatry, 26, 41–50.

Cranston, K., Alpren, C., John, B., Dawson, E., Roosevelt, K., Burrage, A., Bryant, J., Switzer, W. M., Breen, C., Peters, P. J., et al. (2019). Notes from the field: HIV diagnoses among persons who inject drugs—Northeastern Massachusetts, 2015–2018. Morbidity and Mortality Weekly Report, 68, 253–254.

Daoust, R., Paquet, J., Lavigne, G., Piette, É., & Chauny, J. (2015). Impact of age, sex and route of administration on adverse events after opioid treatment in the emergency department: A retrospective study. Pain Research and Management, 20, 23–28.

Day, L., Kleinschmidt, K., Forrester, M. B., & Feng, S.-Y. (2016). Comparison of unintentional exposures to codeine and hydrocodone reported to Texas poison centers. Journal of Emergency Medicine, 50, 744–752.

Drewes, A. M., Jensen, R. D., Nielsen, L. M., Droney, J., Christrup, L. L., Arendt-Nielsen, L., Riley, J., & Dahan, A. (2013). Differences between opioids: Pharmacological, experimental, clinical and economical perspectives. British Journal of Clinical Pharmacology, 75, 60–78.

Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. Lancet, 356, 1255–1259.

European Medicines Agency. (2014). Guideline on Good Pharmacovigilance Practices (GVP), Module VI—Management and Reporting of Adverse Reactions to Medicinal Products, 1st Revised. European Medicines Agency and Heads of Medicines Agencies.

Ferner, R. E., & Aronson, J. K. (2006). Clarification of terminology in medication errors: Definitions and classification. Drug Safety, 29, 1011–1022.

Ferner, R. E., & McGettigan, P. (2018). Adverse drug reactions. BMJ, 363, k4051.

Ferner, R. E., Easton, C., & Cox, A. R. (2018). Deaths from medicines: A systematic analysis of coroners’ reports to prevent future deaths. Drug Safety, 41, 103–110.

Fields, H. L. (2011). The doctor’s dilemma: Opiate analgesics and chronic pain. Neuron, 69, 591–594.

Gandhi, T. K., Seger, D. L., & Bates, D. W. (2000). Identifying drug safety issues: From research to practice. International Journal for Quality in Health Care, 12, 69–76.

Gariel, C., Cogniat, B., Desgranges, F. P., Chassard, D., & Bouvet, L. (2018). Incidence, characteristics, and predictive factors for medication errors in paediatric anaesthesia: A prospective incident monitoring study. British Journal of Anaesthesia, 120, 563–570.

Gustafsson, M., Matos, C., Joaquim, J., Scholl, J., & van Hunsel, F. (2023). Adverse drug reactions to opioids: A study in a national pharmacovigilance database. Drug Safety, 46, 1133–1148.

Harris, E., Harms, M., Cao, D., Prestwood, C., DeBinya, L., Kleinschmidt, K., Young, A., Saha, S., Rule, J., & Alvarez, K. (2023). Declining rates of opioid/acetaminophen combination product overdose: 2011–2020. Hepatology Communications, 7, e0067.

Health, T. L. (2022). Opioid overdose crisis: Time for a radical rethink. Lancet Public Health, 7, e195.

Hedegaard, H., Miniño, A. M., & Warner, M. (2020). Drug overdose deaths in the United States, 1999–2018 (NCHS Data Brief No. 356). National Center for Health Statistics.

Heneka, N., Shaw, T., Rowett, D., Lapkin, S., & Phillips, J. L. (2018). Exploring factors contributing to medication errors with opioids in Australian specialist palliative care inpatient services: A multi-incident analysis. Journal of Palliative Medicine, 21, 82.

Hicks, R. W., Becker, S. C., & Cousins, D. D. (2006). Harmful medication errors in children: A 5-year analysis of data from the USP’s MEDMARX® program. Journal of Pediatric Nursing, 21, 290–298.

Hoffman, E., Watson, J., Sauver, J., Staff, N., & Klein, C. (2017). Association of long-term opioid therapy with functional status, adverse outcomes, and mortality among patients with polyneuropathy. JAMA Neurology, 74, 773.

Ing Lorenzini, K., Wainstein, L., Spechbach, H., Sarasin, F., Ramlawi, M., Desmeules, J., & Piguet, V. (2022). Opioid-related adverse drug reactions in patients visiting the emergency division of a tertiary hospital. Pharmacology Research & Perspectives, 10, e01033.

Jay, G. W., Heit, H. A., & Gourlay, D. L. (2019). When the best of intentions leads to bad outcomes. Pain Therapy, 8, 1–4.

Jobski, K., Bantel, C., & Hoffmann, F. (2023). Characteristics and completeness of spontaneous reports by reporter’s role in Germany: An analysis of the EudraVigilance database using the example of opioid-associated abuse, dependence, or withdrawal. Pharmacology Research & Perspectives, 11, e01077.

Jones, C., Einstein, E., & Compton, W. (2018). Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016. JAMA, 319, 1819.

Kalkman, G. A., van den Brink, W., Pierce, M., Atsma, F., Vissers, K. C. P., Schers, H. J., van Dongen, R. T. M., Kramers, C., & Schellekens, A. F. A. (2022). Monitoring opioids in Europe: The need for shared definitions and measuring drivers of opioid use and related harms. European Addiction Research, 28, 231–240.

Laurence, D. R., & Carpenter, J. (1998). A Dictionary of Pharmacology and Allied Topics. Elsevier.

Lövborg, H., Holmlund, M., & Hägg, S. (2014). Medication errors related to transdermal opioid patches: Lessons from a regional incident reporting system. BMC Pharmacology and Toxicology, 15, 1–6.

Lovegrove, M. C., Weidle, N. J., & Budnitz, D. S. (2015). Trends in emergency department visits for unsupervised pediatric medication exposures, 2004–2013. Pediatrics, 136, e821–e829.

Lynn, E., Cousins, G., Lyons, S., & Bennett, K. E. (2021). Trends in drug poisoning deaths, by sex, in Ireland: A repeated cross-sectional study from 2004 to 2017. BMJ Open, 11, e048000.

Macey, T., Bobeck, E., Hegarty, D., Aicher, S., Ingram, S., & Morgan, M. (2009). Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat. Journal of Pharmacology and Experimental Therapeutics, 331, 412–418.

Maier, C., Schaub, C., Willweber-Strumpf, A., & Zenz, M. (2005). Long-term efficiency of opioid medication in patients with chronic non-cancer-associated pain: Results of a survey 5 years after onset of medical treatment. Der Schmerz, 19, 410–417.

Manchikanti, L., Sanapati, J., Benyamin, R. M., Atluri, S., Kaye, A. D., & Hirsch, J. A. (2018). Reframing the prevention strategies of the opioid crisis: Focusing on prescription opioids, fentanyl, and heroin epidemic. Pain Physician, 21, 309.

Matos, C., Rodrigues, L., & Joaquim, J. (2017). Attitudes and opinions of Portuguese community pharmacy professionals towards patient reporting of adverse drug reactions and the pharmacovigilance system. Drugs & Therapy Perspectives, 33, 188–194.

Mc Donnell, C. (2011). Opioid medication errors in pediatric practice: Four years’ experience of voluntary safety reporting. Pain Research and Management, 16, 93–98.

Mojtabai, R., Amin-Esmaeili, M., Nejat, E., & Olfson, M. (2019). Misuse of prescribed opioids in the United States. Pharmacoepidemiology and Drug Safety, 28, 345–353.

Morimoto, T., Gandhi, T. K., Seger, A. C., Hsieh, T. C., & Bates, D. W. (2004). Adverse drug events and medication errors: Detection and classification methods. Quality and Safety in Health Care, 13, 306–314.

Moulis, F., Durrieu, G., Masmoudi, K., Boyer, M. G., Rocher, F., Montastruc, F., & Montastruc, J.-L. (2018). Medication errors with tramadol drops in children. European Journal of Clinical Pharmacology, 74, 247–248.

Mullan, J., Burns, P., Mohanan, L., Lago, L., Jordan, M., & Potter, J. (2019). Hospitalisation for medication misadventures among older adults with and without dementia: A 5-year retrospective study. Australasian Journal on Ageing, 38, e135–e141.

Ni, J., Tang, X., & Chen, L. (2023). Medication overdose data analysis: A review of medication error reports in the FDA adverse event reporting system (FAERS). BMC Pharmacology and Toxicology, 24, 41.

Ostling, P. S., Davidson, K. S., Anyama, B. O., Helander, E. M., Wyche, M. Q., & Kaye, A. D. (2018). America’s opioid epidemic: A comprehensive review and look into the rising crisis. Current Pain and Headache Reports, 22, 1–7.

Parliament, E., & The Council of the European Union. (2010). Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. OJ, 348, 74–99.

Pathan, H., & Williams, J. (2012). Basic opioid pharmacology: An update. British Journal of Pain, 6, 11–16.

Phillips, J. K., Ford, M. A., & Bonnie, R. J. (Eds.). (2017). Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. National Academies Press.

Polati, E., Nizzero, M., Rama, J., Martini, A., Gottin, L., Donadello, K., Del Balzo, G., Varrassi, G., Marinangeli, F., Vittori, A., et al. (2022). Oxycodone-naloxone combination hinders opioid consumption in osteoarthritic chronic low back pain: A retrospective study with two years of follow-up. International Journal of Environmental Research and Public Health, 19, 13354.

Radbruch, L., Glaeske, G., Grond, S., Münchberg, F., Scherbaum, N., Storz, E., Tholen, K., Zagermann-Muncke, P., Zieglgänsberger, W., & Hoffmann-Menzel, H. (2013). Topical review on the abuse and misuse potential of tramadol and tilidine in Germany. Substance Abuse, 34, 313–320.

Rashed, A. N., Wong, I. C., Cranswick, N., Hefele, B., Tomlin, S., Jackman, J., Lee, K., Hon, K. L., Ong, J., Ghaleb, M., et al. (2012). Adverse drug reactions in children—International surveillance and evaluation (ADVISE) A multicentre cohort study. Drug Safety, 35, 481–494.

Ratycz, M. C., Papadimos, T. J., & Vanderbilt, A. A. (2018). Addressing the growing opioid and heroin abuse epidemic: A call for medical school curricula. Medical Education Online, 23, 1466574.

Sabblah, G. T., Seaneke, S. K., Kushitor, M., van Hunsel, F., Taxis, K., Duwiejua, M., & van Puijenbroek, E. (2022). Evaluation of pharmacovigilance systems for reporting medication errors in Africa and the role of patients using a mixed-methods approach. PLoS ONE, 17, e0264699.

Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019). Assessing the 2004–2018 fentanyl misusing issues reported to an international range of adverse reporting systems. Frontiers in Pharmacology, 10, 428774.

Seth, P. (2018). Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morbidity and Mortality Weekly Report, 67, 349–358.

Shei, A., Hirst, M., Kirson, N., Enloe, C., Birnbaum, H., & Dunlop, W. (2015). Estimating the health care burden of prescription opioid abuse in five European countries. ClinicoEconomics and Outcomes Research, 7, 477–488.

Smith, M., Kong, D., Kuo, A., Imam, M., & Williams, C. (2022). Analgesic opioid ligand discovery based on nonmorphinan scaffolds derived from natural sources. Journal of Medicinal Chemistry, 65, 1612–1661.

Stein, C. (2016). Opioid receptors. Annual Review of Medicine, 67, 433–451.

Trojan, A., & Beil, H. W. (1978). Tilidine abuse and dependence. Drug and Alcohol Dependence, 3, 383–391.

van Hoof, M., Chinchilla, K., Härmark, L., Matos, C., Inácio, P., & van Hunsel, F. (2022). Factors contributing to best practices for patient involvement in pharmacovigilance in Europe: A stakeholder analysis. Drug Safety, 45, 1083–1098.

van Hunsel, F., & Ekhart, C. (2021). Unexpected beneficial effects of drugs: An analysis of cases in the Dutch spontaneous reporting system. European Journal of Clinical Pharmacology, 77, 1543–1551.

Vijayvargiya, P., Camilleri, M., Vijayvargiya, P., Erwin, P., & Murad, M. (2020). Systematic review with meta-analysis: Efficacy and safety of treatments for opioid-induced constipation. Alimentary Pharmacology and Therapeutics, 52, 37–53.

Volkow, N., & Koroshetz, W. (2017). Lack of evidence for benefit from long-term use of opioid analgesics for patients with neuropathy. JAMA Neurology, 74, 761.

Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004). Opioid receptors. Annual Review of Biochemistry, 73, 953–990.

Whipple, J. K., Ausman, R. K., & Quebbeman, E. J. (1992). Narcotic use in the hospital: Reasonably safe? SAGE Publications.

World Health Organization. (1972). International drug monitoring: The role of national centres. In Proceedings of the Report of a WHO Meeting, Geneva, Switzerland, 20–25 September 1971. World Health Organization.